Adjusting eptifibatide doses for renal impairment: A model of dosing agreement among various methods of estimating creatinine clearance;Ajuste de la Dosis de Eptifibatide Para la Insuficiencia Renal: Un Acuerdo de Modelo de Dosificación Entre Varios Métodos de Estimación del Aclaramiento de Creatinina

Annals of Pharmacotherapy

Volumn 46, Issue 4, 2012, Pages 477-483

  Healy, Martha F ^a   Speroni, Karen Gabel ^a   Eugenio, Kenneth R ^b   Murphy, Patricia M ^c  

^a Inova Loudoun Hospital   (United States)

^b St Luke's and Tobey Hospitals   (United States)

^c INOVA HEART AND VASCULAR INSTITUTE   (United States)

Author keywords

Cockcroft Gault; Creatinine clearance; Eptifibatide; Renal dosing; Renal dysfunction

Indexed keywords

CREATININE; EPTIFIBATIDE;

ADULT; AGED; ARTICLE; BLEEDING; BODY WEIGHT; CONTINUOUS INFUSION; CREATININE CLEARANCE; DOSE CALCULATION; DRUG EFFICACY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICATION ERROR; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; URINARY EXCRETION;

AGED; AGED, 80 AND OVER; BODY WEIGHT; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; FEMALE; GLOMERULAR FILTRATION RATE; HEMORRHAGE; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PEPTIDES; PLATELET AGGREGATION INHIBITORS; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES;

EID: 84859712907     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q644     Document Type: Article

References (37)

1. Product information. Integrilin (eptifibatide). Kenilworth, NJ: Schering Corporation, March 2011.
2. Gretler DD, Guerciolini R, Williams PJ. Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function. Clin Ther 2004;26:390-8. DOI 10.1016/S0149-2918(04)90034-3
3. Cockcroft DW, Gault HM. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41. DOI 10.1159/000180580
4. Dowling TC, Matzke GTR, Murphy JE. Evaluation of renal drug dosing: prescribing information and clinical pharmacist approaches. Pharmacotherapy 2010;30:787-96. DOI 10.1592/phco.30.8.776
5. Wolowich WR, Raymo L, Rodriguez JC. Problems with the use of the Modified Diet in Renal Disease formula to estimate renal function. Pharmacotherapy 2005;25:1283-5. DOI 10.1592/phco.2005.25.9.1283
6. Bauer L. Creatinine clearance versus glomerular filtration rate for the use of renal drug dosing in patients with kidney dysfunction. Pharmacotherapy 2005;25:1286-7. DOI 10.1592/phco.2005.25.9.1286
7. Lam SW, Eschenauer GA. Identifying patients at risk of chronic kidney disease (letter). Am Fam Physician 2007;76:1454.
8. Rigalleau V, Lasseur C, Perlemoine C, et al. Cockcroft-Gault formula is biased by body weight in diabetic patients with renal impairment. Metabolism 2005;55:108-12. DOI 10.1016/j.metabol.2005.07.014
9. Rosborough TK, Shepherd MF, Couch PL. Selecting an equation to estimate glomerular filtration rate for use in renal dosage adjustment of drugs in electronic patient record systems. Pharmacotherapy 2005;25:823-30.
10. Hailemeskel B, Lakew D, Yohannes L, et al. Creatinine clearance estimation in elderly patients using the Cockcroft and Gault equation with ideal, actual, adjusted, or no body weight. Consult Pharm 1999;14:72-5.
11. Golik MV, Lawrence KR. Comparison of dosing recommendations for antimicrobial drugs based on two methods for assessing kidney function: Cockcroft-Gault and Modification of Diet in Renal Disease. Pharmacotherapy 2008;28:1125-32. DOI 10.1592/phco.28.9.1125
12. Planet G. Comparison of creatinine clearance estimates with routine measured clearance. Clin Biochem 2007;40:124-7. DOI 10.1016/j.clinbiochem.2006.08.001
13. Davis GA, Chandler MH. Comparison of creatinine clearance estimation methods in patients with trauma. Am J Health Syst Pharm 1996;53: 1028-31.
14. Stevens LA, Nolin TD, Richardson MM, et al. Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations. Am J Kidney Dis 2009;54:33-42. DOI 10.1053/j.ajkd.2009.03.008
15. Lim WH, McDonald S. Lean body mass-adjusted Cockcroft and Gault formula improves the estimation of glomerular filtration rate in subjects with normal-range serum creatinine. Nephrology 2006;11:250-6. DOI 10.1111/j.1440-1797.2006.00560.x
16. Spinler SS, Nawarskas JJ, Boyce EG, et al. Predictive performance of ten equations for estimating creatinine clearance in cardiac patients. Ann Pharmacother 1998;32:1275-83. DOI 10.1345/aph.18122
17. Product information. Tikosyn (dofetilide). New York, NY: Pfizer Inc., February 2011.
18. Product information. Alimta (pemetrexed). Indianapolis, IN: Eli Lilly & Co., November 2011.
19. Product information. Cubicin (daptomycin). Lexington, MA: Cubist Pharmaceuticals, November 2010.
20. Product information. Hepsera (adefovir). Foster City, CA: Gilead Sciences, October 2009.
21. Product information. Viread (tenofovir). Foster City, CA: Gilead Sciences, November 2011.
22. Hermsen ED, Maiefski M, Florescu MC, et al. Comparison of the Modification of Diet in Renal Disease and Cockcroft-Gault equations for dosing antimicrobials. Pharmacotherapy 2009;29:649-55. DOI 10.1592/phco.29.6.649
23. Froissart M, Rossert J, Jacquot C, et al. Predictive performance of the Modification of Diet in Renal Disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol 2005;16:763-73.
24. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-70.
25. Guidance for industry: pharmacokinetics in patients with impaired renal function-study design, data analysis, and impact on dosing and labeling. Washington, DC: Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Draft guidance. March 2010. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM204959.pdf (accessed 2010 Nov 19).
26. Melloni C, Peterson ED, Chen AY, et al. Cockcroft-Gault versus Modification of Diet in Renal Disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 2008;51:991-6. DOI 10.1016/j.jacc.2007.11.045
27. Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 2005;294:3108-16. DOI 10.1001/jama.294.24.3108
28. Moscucci M, Fox KA, Cannon CP, et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003;24:1815-23. DOI 10.1016/S0195-668X(03)00485-8
29. O'Shea JC, Madan M, Cantor WJ, et al. Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention. Am Heart J 2000;140:834-9. DOI 10.1067/mhj.2000.110458
30. Tcheng JE, O'Shea JC, Cohen EA, et al. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo-controlled trial. Lancet 2000;354:2037-44.
31. The Impact II Investigators. Randomised placebo-controlled trial of effect on complications of percutaneous coronary intervention: IMPACT II (Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II). Lancet 1997;349:1422-8. DOI 10.1016/S0140-6736(96)10172-0
32. Gold HK, Gimple LW, Yasuda T, et al. Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest 1990;86:651-9. DOI 10.1172/JCI114757
33. Tcheng JE, Thel MC, Jennings L, et al. Platelet glycoprotein IIb/IIIa receptor blockade with high-dose Integrilin in coronary intervention: results of the PRIDE study. Eur Heart J 1997;18:P3615.
34. Reddan DN, O'Shea JC, Sarembock IJ, et al. Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT trial). Am J Cardiol 2003;91:17-21. DOI 10.1016/S0002-9149(02)02991-0
35. Altman DG. Practical statistics for medical research. London, England: Chapman and Hall, 1991:404.
36. National Institute of Diabetes and Digestive and Kidney Diseases and National Kidney Disease Education Program. Chronic kidney disease and drug dosing: information for providers (September 2009). http:// nkdep.nih.gov/professionals/CKD_DrugDosing_508.pdf (accessed 2010 Nov 19).
37. Nyman HA, Dowling TC, Hudson JQ, et al. Comparative evaluation of the Cockcroft-Gault equation and the Modification of Diet in Renal Disease (MDRD) study equation for drug dosing: an opinion of the Nephrology Practice and Research Network of the American College of Clinical Pharmacy. Pharmacotherapy 2011;31:1130-44. DOI 10.1592/phco.31.11.1130.